The potential prognostic utility of salivary galectin-3 concentrations in heart failure.
Xi ZhangNuwan KarunathilakaSameera SenanayakeV Nathan SubramaniamWandy ChanKaram KostnerJohn FraserJohn J AthertonChamindie PunyadeeraPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2019)
In our pilot study, HF patients with salivary Gal-3 concentrations of > 172.58 ng/mL demonstrated a higher cumulative risk of the primary outcome compared to those with lower Gal-3 levels, even after adjusting for other variables. Confirming our findings in a larger multi-centre clinical trial in the future would enable salivary Gal-3 measurements to form part of routine management for patients with HF.